← Eichor
Study identifier: NCT07269717 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction

Condition: Heart Failure With Preserved Ejection Fraction  ·  Sponsor: Shandong Suncadia Medicine Co., Ltd.

PhasePhase 2
Planned participants48
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to evaluate the safety and tolerability of HRS-1893 in subjects with heart failure with preserved ejection fraction.

This description comes directly from the study's public registry record.

Talk to the study team

Jianhong Lv  ·  +86-0518-82342973  ·  jianhong.lv.jl9@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

Zhongshan Hospital Affiliated to Fudan UniversityShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07269717